Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine-18-THK 5351

Next Previous
Drug Profile

Fluorine-18-THK 5351

Alternative Names: 3H-THK5351; [18F]THK-5351; F-18 THK-5351; FluoroTau; GE-216

Latest Information Update: 02 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tohoku University
  • Developer Chang Gung Memorial Hospital; Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; GE Healthcare; Tohoku University
  • Class Imaging agents; Pyridines; Quinolines; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Cognition disorders; Neurodegenerative disorders
  • No development reported Aphasia; Lewy body disease; Mild cognitive impairment; Progressive supranuclear palsy

Most Recent Events

  • 02 Jan 2023 Phase-III development is ongoing in Belgium (IV) (EudraCT2016-001436-35)
  • 05 Oct 2021 Phase-II development is ongoing in Taiwan (NCT04588649)
  • 23 Oct 2020 Chang Gung Memorial Hospital completes a phase II trial in Vascular dementia (Diagnosis, In adults, In elderly) in Taiwan (NCT04588649)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top